Belite Bio (BLTE) Short term Debt (2021)

Belite Bio (BLTE) posted quarterly Short term Debt of $71000.0 for Q4 2021.

Belite Bio (BLTE) Short term Debt (2021) Analysis & Trends

Belite Bio's Short term Debt history runs 1 years deep, the most recent figure standing at $71000.0 for Q4 2021.

In Q4 2021, Short term Debt changed N/A year-over-year to $71000.0; the TTM figure through Dec 2021 stood at $71000.0 (changed N/A YoY), while the FY2021 annual figure was $71000.0, changed N/A from the prior year.
Short term Debt for Q4 2021 stood at $71000.0.
The five-year high for Short term Debt was $71000.0 in Q4 2021, with the low at $71000.0 in Q4 2021.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Belite Bio	6.40 Bn	6.40 Bn	-

Historic Data

Download Data

Date	Value
Dec 31, 2021	71,000.00